Although the jury found the claims valid, and the Fed. Cir. affirmed, this decision, which found that the claims were not insolubly ambiguous, was revisited by the Fed. Cir. While there are pages on issue preclusion, in the end, the Fed. Cir. took the appeal and reversed its original position. Here there were four possible […]
The post Another Claim Bites the Dust left by Teva v. Sandoz appeared first on Biotechnology Patent Law Blog | Patents4Life by Warren Woessner.